Cutaneous Lupus Erythematosus – Pipeline Review, H2 2012

Cutaneous Lupus Erythematosus – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012', provides an overview of the Cutaneous Lupus Erythematosus therapeutic pipeline. This report provides information on the therapeutic development for Cutaneous Lupus Erythematosus, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Cutaneous Lupus Erythematosus. 'Cutaneous Lupus Erythematosus - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Cutaneous Lupus Erythematosus.
- A review of the Cutaneous Lupus Erythematosus products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Cutaneous Lupus Erythematosus pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Cutaneous Lupus Erythematosus.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Cutaneous Lupus Erythematosus pipeline depth and focus of Cutaneous Lupus Erythematosus therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Cutaneous Lupus Erythematosus Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Cutaneous Lupus Erythematosus 7
Cutaneous Lupus Erythematosus Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Cutaneous Lupus Erythematosus Therapeutics – Products under Development by Companies 12
Companies Involved in Cutaneous Lupus Erythematosus Therapeutics Development 13
Amgen Inc. 13
Rigel Pharmaceuticals, Inc. 14
Celgene Corporation 15
Tolerx, Inc. 16
Cutaneous Lupus Erythematosus – Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Drug Profiles 22
AMG 811 - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
AMG 557 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
JNK CC-930 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
CC-11050 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
TRX1 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
R-333 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Cutaneous Lupus Erythematosus Therapeutics – Drug Profile Updates 30
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Cutaneous Lupus Erythematosus, H2 2012 7
Products under Development for Cutaneous Lupus Erythematosus – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Amgen Inc., H2 2012 13
Rigel Pharmaceuticals, Inc., H2 2012 14
Celgene Corporation, H2 2012 15
Tolerx, Inc., H2 2012 16
Assessment by Monotherapy Products, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 21
Cutaneous Lupus Erythematosus Therapeutics – Drug Profile Updates 30

List of Figures
Number of Products under Development for Cutaneous Lupus Erythematosus, H2 2012 7
Products under Development for Cutaneous Lupus Erythematosus – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 17
Assessment by Route of Administration, H2 2012 18
Assessment by Stage and Route of Administration, H2 2012 19
Assessment by Molecule Type, H2 2012 20
Assessment by Stage and Molecule Type, H2 2012 21